Mga Batayang Estadistika
| CIK | 1361248 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to TetraLogic Pharmaceuticals Corporation
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U109 (CUSIP Number) September 23, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate b |
|
| February 15, 2019 |
TLOG / TetraLogic Pharmaceuticals Corporation / Robins David C. - AMENDMENT NO. 5 Passive Investment SC 13G/A 1 j215190sc13ga5.htm AMENDMENT NO. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U109 (CUSIP Number) February 15, 2019 (Date of Event Which Requires Fili |
|
| September 19, 2017 |
TLOG / TetraLogic Pharmaceuticals Corporation / Robins David C. - AMENDMENT NO. 4 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U109 (CUSIP Number) September 19, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate b |
|
| September 18, 2017 |
TLOG / TetraLogic Pharmaceuticals Corporation / Robins David C. - AMENDMENT NO. 3 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U109 (CUSIP Number) September 15, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate b |
|
| August 30, 2017 |
TLOG / TetraLogic Pharmaceuticals Corporation / Robins David C. - AMENDMENT NO. 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U109 (CUSIP Number) August 29, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box |
|
| August 17, 2017 |
TLOG / TetraLogic Pharmaceuticals Corporation / Robins David C. - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U109 (CUSIP Number) August 17, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box |
|
| August 4, 2017 |
TLOG / TetraLogic Pharmaceuticals Corporation / Robins David C. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U109 (CUSIP Number) August 1, 2017 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to d |
|
| December 2, 2016 |
TetraLogic Pharmaceuticals 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36208 TetraLogic Pharmaceuticals Corporation (Exact name of registrant a |
|
| December 1, 2016 |
TetraLogic Pharmaceuticals DEF 14A DEF 14A 1 a2230427zdef14a.htm DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box |
|
| November 22, 2016 |
TetraLogic Pharmaceuticals PREM14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 22, 2016 |
TetraLogic Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2016 (November 18, 2016) TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| November 22, 2016 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES A CONVERTIBLE PARTICIPATING PREFERRED STOCK OF TETRALOGIC PHARMACEUTICALS CORPORATION Pursuant to Section 151 of the General Corporation Law of the State of Delaware, TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), in accordance with the prov |
|
| November 14, 2016 |
FORM OF EXCHANGE AND CONSENT AGREEMENT Exhibit 10.1 FORM OF EXCHANGE AND CONSENT AGREEMENT EXCHANGE AND CONSENT AGREEMENT (this ?Agreement?), dated as of November 14, 2016, by and between TetraLogic Pharmaceuticals Corporation, a Delaware corporation, with offices located at 343 Phoenixville Pike, Malvern, PA 19355 (the ?Company?), and each of the Noteholders listed on Schedule 1 attached hereto (collectively, the ?Noteholders? and eac |
|
| November 14, 2016 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2016 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U 109 (CUSIP Number) John Oliva Highbridge Capital Management, LLC 40 West 57th Street, 32nd Floor New York, New York 100 |
|
| November 14, 2016 |
TLOG / TetraLogic Pharmaceuticals Corporation / Linden Advisors LP - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U 109 (CUSIP Number) Saul S. Ahn Linden Advisors LP 590 Madison Ave., 15th floor New York, NY 10022 646-840-3642 (Name, Ad |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U 109 (CUSIP Number) 777 3rd Ave, New York, NY 10017 (Name, Address and Telephone Number of Person Authorized to Receive N |
|
| November 14, 2016 |
Exhibit 99.A EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock of TetraLogic Pharmaceuticals Corpora dated November 14, 2016 is, and any further amendments thereto signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) un |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U 109 (CUSIP Number) Christopher McDonough Director State of New Jersey Division of Investment 50 West State Street, 9th F |
|
| November 14, 2016 |
SC 13D 1 a16-215781sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U 109 (CUSIP Number) Geode Capital Management LP One Post Office Square, 20th Floor Bo |
|
| November 14, 2016 |
TetraLogic Pharmaceuticals SC 13D (Activist Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U 109 (CUSIP Number) Nomura Securities International, Inc. Worldwide Plaza, 309 West 49th Street New York, NY 10019-7316 P |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U 109 (CUSIP Number) Dan Sommers Telemetry Investments LLC 545 Fifth Avenue, Suite 1108 New York, NY 10017 (212) 425-9700 |
|
| November 14, 2016 |
IDENTIFICATION OF MEMBERS OF THE GROUP Exhibit 99.B EXHIBIT B IDENTIFICATION OF MEMBERS OF THE GROUP Linden Advisors LP Linden Capital L.P. Linden GP LLC Siu Min Wong |
|
| November 14, 2016 |
TLOG / TetraLogic Pharmaceuticals Corporation / WHITEBOX ADVISORS LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U 109 (CUSIP Number) Mark Strefling Whitebox Advisors LLC 3033 Excelsior Boulevard Suite 300 Minneapolis, MN 55416 (612) 2 |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U 109 (CUSIP Number) Nomura Securities International, Inc. Worldwide Plaza, 309 West 49th Street New York, NY 10019-7316 P |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36208 TetraLogic Pharmaceuticals Corporation, The Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/o |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U109 (CUSIP Number) Mark Anderson, Chief Compliance Officer Lazard Asset Management LLC 30 Rockefeller Plaza New York, Ne |
|
| November 14, 2016 |
EX-99.A 2 a16-215771ex99da.htm EX-99.A Exhibit A The name, business address, present principal employment and citizenship of each executive officer of Telemetry Securities LLC is set forth below. Name Business Address Present Principal Employment Citizenship Andrew Schorr Telemetry Investments LLC 545 Fifth Avenue Suite 1108 New York, NY 10017 CEO of Telemetry Securities, LLC USA Daniel Schorr Tel |
|
| November 3, 2016 |
8-K 1 a16-2102518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2016 (October 30, 2016) TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-160475 |
|
| November 3, 2016 |
TETRALOGIC PHARMACEUTICALS CORPORATION Debt Exchange November 2, 2016 Exhibit 10.2 EXECUTION COPY TETRALOGIC PHARMACEUTICALS CORPORATION Debt Exchange November 2, 2016 WHEREAS, concurrently with the execution of an asset purchase agreement (the ?APA?) between TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the ?Issuer?), and Medivir AB, a company organized under the laws of Sweden (?Medivir?), for the sale of substantially all of the Issuer?s assets |
|
| November 3, 2016 |
Exhibit 10.1 EXECUTION COPY ASSET PURCHASE AGREEMENT BY AND AMONG TETRALOGIC PHARMACEUTICALS CORPORATION, TETRALOGIC RESEARCH AND DEVELOPMENT CORPORATION AND MEDIVIR AB DATED AS OF NOVEMBER 2, 2016 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this ?Agreement?) is made and entered into as of this 2nd day of November, 2016 by and among TetraLogic Pharmaceuticals Corporation, a Delaware co |
|
| November 3, 2016 |
EX-99.1 5 a16-210251ex99d1.htm EX-99.1 Exhibit 99.1 TetraLogic Announces Agreements to Sell SMAC mimetic and HDAC inhibitor assets to Medivir and to Restructure its Convertible Senior Notes and Delisting of Common Stock PAOLI, PA., November 2, 2016 — TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG) (“TetraLogic” or “Company”), a clinical-stage biopharmaceutical company focused on discovering |
|
| November 3, 2016 |
EXHIBIT 10.3 EXECUTION VERSION VOTING AGREEMENT THIS VOTING AGREEMENT (this Agreement) is made and entered into as of November 2, 2016, by and among TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the Company), and each of the undersigned stockholders (each, a Stockholder and collectively, the Stockholders) of the Companys common stock, $0.0001 par value per share (the Co |
|
| November 3, 2016 |
TetraLogic Pharmaceuticals 10-Q (Quarterly Report) tlogCurrent folio10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 3, 2016 |
TetraLogic Pharmaceuticals 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 3, 2016 (October 30, 2016) TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| November 3, 2016 |
Exhibit 10.1 EXECUTION COPY ASSET PURCHASE AGREEMENT BY AND AMONG TETRALOGIC PHARMACEUTICALS CORPORATION, TETRALOGIC RESEARCH AND DEVELOPMENT CORPORATION AND MEDIVIR AB DATED AS OF NOVEMBER 2, 2016 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this ?Agreement?) is made and entered into as of this 2nd day of November, 2016 by and among TetraLogic Pharmaceuticals Corporation, a Delaware co |
|
| November 3, 2016 |
EX-99.1 5 a16-210251ex99d1.htm EX-99.1 Exhibit 99.1 TetraLogic Announces Agreements to Sell SMAC mimetic and HDAC inhibitor assets to Medivir and to Restructure its Convertible Senior Notes and Delisting of Common Stock PAOLI, PA., November 2, 2016 — TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG) (“TetraLogic” or “Company”), a clinical-stage biopharmaceutical company focused on discovering |
|
| November 3, 2016 |
EXHIBIT 10.3 EXECUTION VERSION VOTING AGREEMENT THIS VOTING AGREEMENT (this ?Agreement?) is made and entered into as of November 2, 2016, by and among TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the ?Company?), and each of the undersigned stockholders (each, a ?Stockholder? and collectively, the ?Stockholders?) of the Company?s common stock, $0.0001 par value per share (the ?Co |
|
| November 3, 2016 |
TETRALOGIC PHARMACEUTICALS CORPORATION Debt Exchange November 2, 2016 EX-10.2 3 a16-210251ex10d2.htm EX-10.2 Exhibit 10.2 EXECUTION COPY TETRALOGIC PHARMACEUTICALS CORPORATION Debt Exchange November 2, 2016 WHEREAS, concurrently with the execution of an asset purchase agreement (the “APA”) between TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Issuer”), and Medivir AB, a company organized under the laws of Sweden (“Medivir”), for the sale of su |
|
| November 3, 2016 |
TetraLogic Pharmaceuticals POS AM As filed with the Securities and Exchange Commission on November 3, 2016 Registration No. |
|
| November 3, 2016 |
TetraLogic Pharmaceuticals S-8 POS S-8 POS 1 a16-210342s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on November 3, 2016 Registration No. 333-192875 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter |
|
| October 19, 2016 |
TetraLogic Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 19, 2016 (October 18, 2016) TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| September 6, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 6, 2016 (September 2, 2016) TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| September 1, 2016 |
8-K 1 a16-1785718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 1, 2016 (August 31, 2016) TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-160475 |
|
| August 11, 2016 |
TetraLogic Pharmaceuticals 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3 |
|
| August 11, 2016 |
EX-10.1 2 tlog-20160630ex1016bc4d6.htm EX-10.1 Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is entered into this 2nd day of May, 2016 (the “Effective Date”) by and between TetraLogic Pharmaceuticals Corporation (“TetraLogic"), a Delaware corporation with its principal place of business located at 343 Phoenixville Pike, Malvern, PA 19355 and Peter Meyers (“Consulta |
|
| July 22, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 22, 2016 (July 19, 2016) TetraLogic Pharmaceuticals Corporation (Exact name of registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| July 20, 2016 |
TetraLogic Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 20, 2016 (July 19, 2016) TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| June 15, 2016 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 15, 2016 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| May 9, 2016 |
POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Richard Sherman as the undersigned's true and lawful attorney-in-fact to: 1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of TetraLogic Pharmaceuticals Corporation (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the S |
|
| May 4, 2016 |
TetraLogic Pharmaceuticals 10-Q (Quarterly Report) tlogCurrent folio10Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2016 |
TetraLogic Pharmaceuticals DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential for Use of |
|
| April 28, 2016 |
TetraLogic Pharmaceuticals DEFINITIVE PROXY STATEMENT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid |
|
| April 7, 2016 |
TetraLogic Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 5, 2016 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| March 16, 2016 |
TetraLogic Pharmaceuticals 10-K (Annual Report) tlogCurrent folio10K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 16, 2016 |
CUSIP No. 88165U 109 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 3) TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock. $0.0001 par value (Title of Class of Securities) 88165U 109 (CUSIP Number) Robert Liptak Clarus Ventures, LLC 101 Main Street, Suite 1210, Cambri |
|
| March 16, 2016 |
SUBSIDIARIES OF TETRALOGIC PHARMACEUTICALS CORPORATION Exhibit 21 SUBSIDIARIES OF TETRALOGIC PHARMACEUTICALS CORPORATION Subsidiary Jurisdiction of Incorporation TetraLogic Research and Development Corporation Delaware Shape Pharmaceuticals Pty Ltd. Australia TetraLogic Birinapant UK Ltd. UK TetraLogic Shape UK Ltd. UK |
|
| February 26, 2016 |
8-K 1 a51288149.htm TETRALOGIC PHARMACEUTICALS CORPORATION 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2016 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 0 |
|
| February 16, 2016 |
EX-99.1 2 t1600069ex99-1.htm EXHIBIT 99.1 CUSIP No. 88165U109 13G Exhibit 99.1 EXHIBIT A JOINT FILING STATEMENT We, the undersigned, hereby express our agreement that the attached statement on Schedule 13G relating to the Common Stock of TetraLogic Pharmaceuticals Corporation is filed on behalf of each of us. Dated: February 16, 2016 NexTech III Oncology, LPCI By: Nextech III GP Ltd. Its: General |
|
| February 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 1) * TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 88165U109 (CUSIP Number) December 31, 2015 (D |
|
| February 10, 2016 |
TLOG / TetraLogic Pharmaceuticals Corporation / WHITEBOX ADVISORS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 5, 2016 |
CUSIP No. 88165U 109 13D Page 1 of 14 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 2) TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock. $0.0001 par value (Title of Class of Securities) 88165U 109 (CUSIP Number) Robert Liptak Clarus Ventures, LLC 101 Main Street, |
|
| February 3, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2016 TetraLogic Pharmaceuticals Corporation (Exact name of registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| January 29, 2016 |
TetraLogic Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 28, 2016 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| January 25, 2016 |
TetraLogic Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 20, 2016 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| January 22, 2016 |
a51264698.htm UNITED STATES SECURITIES AN D EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 19, 2016 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction |
|
| January 11, 2016 |
EX-99.1 2 a51255633ex991.htm EXHIBIT 99.1 Exhibit 99.1 TetraLogic Pharmaceuticals Announces Data on Lead Clinical Programs Birinapant Shows No Activity in Randomized Phase 2 MDS Study SHAPE Shows Clinical Benefit in Randomized Phase 2 CTCL Study MALVERN, Pa., January 6, 2016 - TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage biopharmaceutical company focused on discovering a |
|
| January 11, 2016 |
TetraLogic Pharmaceuticals TETRALOGIC PHARMACEUTICALS CORPORATION (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2016 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| December 9, 2015 |
a51240170.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2015 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction o |
|
| November 5, 2015 |
TetraLogic Pharmaceuticals 3G (Passive Acquisition of More Than 5% of Shares) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 28, 2015 |
EXHIBIT 99.1 |
|
| September 28, 2015 |
TetraLogic Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2015 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| August 25, 2015 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| August 25, 2015 |
Exhibit 10.1 PURCHASE AGREEMENT PURCHASE AGREEMENT (the ?Agreement?), dated as of August 24, 2015, by and between TETRALOGIC PHARMACEUTICALS CORPORATION, a Delaware corporation, (the ?Company?), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the ?Investor?). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Inves |
|
| August 25, 2015 |
Entry into a Material Definitive Agreement 8-K 1 a15-1843618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 24, 2015 TETRALOGIC PHARMACEUTICALS CORPORATION (Exact name of Registrant as Specified in Charter) Delaware 001-36208 42-1604756 (State or Other Jurisd |
|
| June 4, 2015 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2015 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| May 1, 2015 |
TetraLogic Announces Public Offering of Common Stock Exhibit 99.1 TetraLogic Announces Public Offering of Common Stock MALVERN, PA., April 30, 2015 ? TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced that it has commenced an underwritten public offering of shares of its common st |
|
| May 1, 2015 |
TetraLogic Announces Pricing of $25 million Public Offering Exhibit 99.2 TetraLogic Announces Pricing of $25 million Public Offering MALVERN, PA., May 1, 2015 TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced that it has priced an underwritten public offering of 6.25 million shares of |
|
| May 1, 2015 |
TetraLogic Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2015 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as Specified in Charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No. |
|
| May 1, 2015 |
TETRALOGIC PHARMACEUTICALS CORPORATION Exhibit 1.1 Execution Version TETRALOGIC PHARMACEUTICALS CORPORATION Common Stock, par value $0.0001 per share Underwriting Agreement May 1, 2015 William Blair & Company, L.L.C., Nomura Securities International, Inc., As representatives of the several Underwriters named in Schedule I hereto, c/o William Blair & Company, L.L.C. 222 West Adams Street Chicago, Illinois 60606 Ladies and Gentlemen: Tet |
|
| May 1, 2015 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. |
|
| April 30, 2015 |
SUBJECT TO COMPLETION, DATED APRIL 30, 2015 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents This preliminary prospectus supplement relates to an effective registration statement under the Securities Act of 1933, but is not complete and may be changed. |
|
| April 30, 2015 |
Exhibit 99.1 |
|
| April 30, 2015 |
TetraLogic Pharmaceuticals FORM 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2015 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| April 20, 2015 |
8-K 1 a15-947218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 20, 2015 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Juri |
|
| April 9, 2015 |
TetraLogic Pharmaceuticals DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy S |
|
| March 30, 2015 |
TetraLogic Pharmaceuticals PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy S |
|
| March 23, 2015 |
TetraLogic Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 18, 2015 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| March 13, 2015 |
TetraLogic Pharmaceuticals 8-K (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 13, 2015 TetraLogic Pharmaceuticals Corporation (Exact Name of Issuer as Specified in Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 001-36208 |
|
| March 13, 2015 |
Table of Contents Filed pursuant to Rule 424(b)(5) Registration No.: 333-201346 Prospectus Supplement (To Prospectus dated January 15, 2015) $25,000,000 Common Stock We have entered into a sales agreement with Guggenheim Securities, LLC, or Guggenheim, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the s |
|
| March 13, 2015 |
TETRALOGIC PHARMACEUTICALS CORPORATION AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT Exhibit 10.1 TETRALOGIC PHARMACEUTICALS CORPORATION AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT March 13, 2015 GUGGENHEIM SECURITIES, LLC 330 Madison Avenue New York, NY 10017 Ladies and Gentlemen: TetraLogic Pharmaceuticals Corporation, a corporation organized under the laws of the State of Delaware (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell |
|
| March 13, 2015 |
TetraLogic Pharmaceuticals FORM 8-K (Current Report/Significant Event) f8k031315.htm UNITED STATES SECURITIES AND EXCHANG E COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2015 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of |
|
| March 3, 2015 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 3, 2015 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| February 13, 2015 |
CUSIP No. 88165U 109 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. 1) TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock. $0.0001 par value (Title of Class of Securities) 88165U 109 (CUSIP Number) Robert Liptak Clarus Ventures, LLC 101 Main Street, Suite 1210, Cambri |
|
| January 2, 2015 |
TLOG / TetraLogic Pharmaceuticals Corporation S-3 - - S-3 S-3 1 a14-266031s3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on January 2, 2015 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TetraLogic Pharmaceuticals Corporation (Exact name of registrant as specified in charter) Delaware 42-1604756 (State or othe |
|
| January 2, 2015 |
Exhibit 4.6 TETRALOGIC PHARMACEUTICALS CORPORATION as the Company and U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of , TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 5 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE 2 THE SECURITIES |
|
| January 2, 2015 |
Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE o Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 31-0841368 I.R.S. Employer Identif |
|
| November 10, 2014 |
EX-10.1 2 a14-241081ex10d1.htm EX-10.1 Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of , 201 by and between TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this |
|
| November 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 5, 2014 TetraLogic Pharmaceuticals Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| November 5, 2014 |
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update Exhibit 99.1 TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update MALVERN, Pa., November 5, 2014 — TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced financial results for the third quarter en |
|
| November 5, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a14-2368618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 5, 2014 TetraLogic Pharmaceuticals Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 001-36208 42-1604756 (State or Other J |
|
| June 23, 2014 |
TETRALOGIC PHARMACEUTICALS CORPORATION 8.00% Convertible Senior Note due 2019 No. 1 $47,000,000 Exhibit 4.2 UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CE |
|
| June 23, 2014 |
Exhibit 4.1 TETRALOGIC PHARMACEUTICALS CORPORATION AS ISSUER 8.00% CONVERTIBLE SENIOR NOTES DUE 2019 INDENTURE Dated as of June 23, 2014 U.S. BANK NATIONAL ASSOCIATION as Trustee TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 12 Section 1.03 Rules of Construction 13 Section 1.04 Acts of Holders 14 ARTICLE 2 TH |
|
| June 23, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2014 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| June 18, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2014 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| June 18, 2014 |
Exhibit 99.1 SUMMARY Unless the context indicates otherwise, as used in this offering memorandum, the terms “TetraLogic,” “we,” “us,” “our,” “our company” and “our business” refer to TetraLogic Pharmaceuticals Corporation and its subsidiaries. Overview We are a clinical-stage biopharmaceutical company focused on discovering, acquiring and developing novel product candidates to treat cancer and inf |
|
| June 18, 2014 |
Exhibit 99.1 June 13, 2014 TetraLogic Pharmaceuticals Announces Conference Call With Dr. Marc Pellegrini of the Walter and Eliza Hall Institute of Medical Research to Discuss TetraLogic Infectious Disease Program MALVERN, Pa., June 13, 2014 (GLOBE NEWSWIRE) TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) (Company) today announced that it will host a conference call and live audio webcast |
|
| June 18, 2014 |
TetraLogic Pharmaceuticals Moderator: Kevin Buchi June 16, 2014 8:00 a.m. ET Exhibit 99.2 TetraLogic Pharmaceuticals Moderator: Kevin Buchi 06-16-14/8:00 a.m. ET Confirmation # 61183614 TetraLogic Pharmaceuticals Moderator: Kevin Buchi June 16, 2014 8:00 a.m. ET Operator: Good morning ladies and gentlemen. Welcome to the TetraLogic Pharmaceuticals conference call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session |
|
| June 18, 2014 |
Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2014 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| June 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2014 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| June 5, 2014 |
TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of April 22, 2014 (“Effective Date”) by and between Richard Sherman a resident of Kilauea, Hawaii (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company” |
|
| May 19, 2014 |
Submission of Matters to a Vote of Security Holders 8-K 1 a14-1310518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2014 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Juris |
|
| April 14, 2014 |
Exhibit 99.1 SHAPE PHARMACEUTICALS, INC. AND SUBSIDIARY (A Development Stage Enterprise) CONSOLIDATED FINANCIAL STATEMENTS YEARS ENDED DECEMBER 31, 2013, 2012 AND 2011 AND FOR THE PERIOD FROM JUNE 11, 2008 (INCEPTION) TO DECEMBER 31, 2013 SHAPE PHARMACEUTICALS, INC. AND SUBSIDIARY (A Development Stage Enterprise) Contents Page Consolidated Financial Statements Independent auditors’ report 1 Balanc |
|
| April 14, 2014 |
Exhibit 99.2 TetraLogic Pharmaceuticals Corporation Pro forma financial information and footnotes for the year ended December 31, 2013 Unless the context requires otherwise, references in this pro forma financial information and footnotes to TetraLogic, Company, we, us, and our are to TetraLogic Pharmaceuticals Corporation and its consolidated subsidiaries, and references to Shape are |
|
| April 14, 2014 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 14, 2014 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| April 11, 2014 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2014 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| April 8, 2014 |
2.60 1.80 2.15 3.30 3.75 5.10 0.15 5.10 4.50 - logo Corporate Presentation April 2014 0.15 Exhibit 99.2 2.60 1.80 2.15 3.30 3.75 5.10 0.15 5.10 4.50 - logo Corporate Presentation April 2014 0.15 Forward-Looking Statements This presentation contains forward-looking statements. These statements are not guarantees of future performance and involve a number of unknown risks, assumptions, trends, uncertainties and factors that are beyond our control. Given these risks, assumptions and uncert |
|
| April 8, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2014 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| April 8, 2014 |
TetraLogic Agrees to Acquire Shape Pharmaceuticals, Inc. Exhibit 99.1 TetraLogic Agrees to Acquire Shape Pharmaceuticals, Inc. · SHAPE, a novel, tissue-targeted topical HDAC inhibitor, is expected to enter Phase 2 trials for early-stage CTCL · Encouraging responses seen in a randomized Phase 1 trial after only 28 days of use, with no significant safety events · SHAPE is designed to avoid systemic absorption and related HDACi toxicities · Adds second cli |
|
| April 2, 2014 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 19, 2014 |
TetraLogic Pharmaceuticals 10-K (Annual Report) Use these links to rapidly review the document TABLE OF CONTENTS TETRALOGIC PHARMACEUTICALS CORPORATION INDEX TO FINANCIAL STATEMENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 13, 2014 |
TLOG / TetraLogic Pharmaceuticals Corporation / PFIZER INC - SCHEDULE 13G Passive Investment SC 13G 1 tl13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 88165U 109 (CUSIP Number) 12/31/2013 (Date of Event Which Requires Filing of this Statement) C |
|
| January 31, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2014 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| January 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 6, 2014 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| December 27, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information To Be Included In Statements Filed Pursuant To § 240.13d-1(b), (c), and (d) and Amendments Thereto Filed Pursuant To § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share ( |
|
| December 27, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information To Be Included In Statements Filed Pursuant To § 240.13d-1(b), (c), and (d) and Amendments Thereto Filed Pursuant To § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock, $0.0001 par value per share ( |
|
| December 27, 2013 |
SC 13G 1 t7802213g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. ) * TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 88165U109 |
|
| December 27, 2013 |
CUSIP No. 88165U 109 13D Page 1 of 17 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) Under the Securities Exchange Act of 1934 (Amendment No. )* TetraLogic Pharmaceuticals Corporation (Name of Issuer) Common Stock. $0.0001 par value (Title of Class of Securities) 88165U 109 (CUSIP Number) Robert Liptak Clarus Ventures, LLC 101 Main Street, |
|
| December 26, 2013 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13D-1(A) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13D-2(A) (Amendment No.)* TETRALOGIC PHARMACEUTICALS CORPORATION (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 88165U 109 (CUSIP Number) Jeffrey B. Ste |
|
| December 18, 2013 |
Exhibit 3.1 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TETRALOGIC PHARMACEUTICALS CORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) TetraLogic Pharmaceuticals Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DG |
|
| December 18, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 17, 2013 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware 001-36208 42-1604756 (State or Other Jurisdiction of Incorporation or Organization) (Commission File Number) (I. |
|
| December 16, 2013 |
QuickLinks - Click here to rapidly navigate through this document As filed with the Securities and Exchange Commission on December 16, 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TetraLogic Pharmaceuticals Corporation (Exact name of Registrant as specified in its charter) Delaware (State or other jurisdiction of Incorporation or organization) 343 Phoenixville Pike Malvern, PA 19355 (Address, including zip code, of Registrant's principal executive offices) 42-1604756 (I. |
|
| December 16, 2013 |
TETRALOGIC PHARMACEUTICAL CORPORATION AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN Exhibit 4.2 TETRALOGIC PHARMACEUTICAL CORPORATION AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN SECTION 1. Purpose; Definitions. The purposes of the Amended and Restated TetraLogic Pharmaceutical Corporation 2013 Equity Incentive Plan (the “Plan”), which supersedes and replaces in its entirety the 2013 Equity Incentive Plan previously approved by the stockholders of TetraLogic Pharmaceutical Cor |
|
| December 16, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION 2004 EQUITY INCENTIVE PLAN Exhibit 4.1 TETRALOGIC PHARMACEUTICALS CORPORATION 2004 EQUITY INCENTIVE PLAN SECTION 1. Purpose; Definitions. The purposes of the Corporation 2004 Equity Incentive Plan (the “Plan”) are to: (a) enable TetraLogic Pharmaceuticals Corporation (the “Company”) and its affiliated companies to recruit and retain highly qualified employees, directors and consultants; (b) provide those employees, director |
|
| December 12, 2013 |
As filed with the Securities and Exchange Commission on December 12, 2013 Registration No. |
|
| December 12, 2013 |
7,150,000 Shares TetraLogic Pharmaceuticals Corporation Common Stock Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents Filed Pursuant to Rule 424(b)(4) Registration File No. |
|
| December 11, 2013 |
December 11, 2013 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 10, 2013 |
Exhibit 3.4 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TETRALOGIC PHARMACEUTICALS CORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) TetraLogic Pharmaceuticals Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DG |
|
| December 10, 2013 |
TetraLogic Pharmaceuticals Corporation 343 Phoenixville Pike Malvern, PA 19355 December 10, 2013 Via EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| December 10, 2013 |
TETRALOGIC PHARMACEUTICAL CORPORATION AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN Exhibit 10.19 TETRALOGIC PHARMACEUTICAL CORPORATION AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN SECTION 1. Purpose; Definitions. The purposes of the Amended and Restated TetraLogic Pharmaceutical Corporation 2013 Equity Incentive Plan (the “Plan”), which supersedes and replaces in its entirety the 2013 Equity Incentive Plan previously approved by the stockholders of TetraLogic Pharmaceutical C |
|
| December 10, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on December 10, 2013 Registration No. |
|
| November 19, 2013 |
TetraLogic Pharmaceuticals Corporation 343 Phoenixville Pike Malvern, PA 19355 November 19, 2013 Via EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| November 18, 2013 |
November 18, 2013 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| November 18, 2013 |
8-A12B 1 a13-2016278a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 TetraLogic Pharmaceuticals Corporation (Exact name of registrant as specified in its charter) Delaware 42-1604756 (State of incorporation or organization) (I.R |
|
| November 18, 2013 |
Exhibit 3.3 AMENDMENT NO. 3 TO THE FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TETRALOGIC PHARMACEUTICALS CORPORATION Pursuant to Section 228 and Section 242 of the General Corporation Law of the State of Delaware (“DGCL”) TetraLogic Pharmaceuticals Corporation, a Delaware corporation (hereinafter called the “Corporation”), does hereby certify as follows: FIRST: That the board of di |
|
| November 18, 2013 |
TetraLogic Pharmaceuticals Corporation 343 Phoenixville Pike Malvern, PA 19355 November 18, 2013 Via EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| November 18, 2013 |
THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT Exhibit 10.18 THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT This Third Amended and Restated Investor Rights Agreement (the “Agreement”) is made as of November 18, 2013, among TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), those stockholders of the Company listed on Exhibit A hereto (individually, a “Common Stockholder,” and collectively, the “Common Stockhol |
|
| November 18, 2013 |
Exhibit 3.4 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TETRALOGIC PHARMACEUTICALS CORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) TetraLogic Pharmaceuticals Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DG |
|
| November 18, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on November 18, 2013 Registration No. |
|
| November 8, 2013 |
QuickLinks - Click here to rapidly navigate through this document The New York Times Building 37th Floor 620 Eighth Avenue New York, NY 10018-1405 212. |
|
| November 6, 2013 |
Exhibit 1.1 Shares TetraLogic Pharmaceuticals Corporation Common Stock ($0.0001 Par Value) EQUITY UNDERWRITING AGREEMENT , 2013 Oppenheimer & Co. Inc. Guggenheim Securities, LLC Needham & Company, LLC As Representative of the Several Underwriters c/o Oppenheimer & Co. Inc. 85 Broad Street, 26th Floor New York, NY 10004 Ladies and Gentlemen: TetraLogic Pharmaceuticals Corporation, a Delaware corpor |
|
| November 6, 2013 |
AMENDMENT NO. 1 TO WARRANT TO PURCHASE EQUITY SECURITIES OF TETRALOGIC PHARMACEUTICALS CORPORATION Exhibit 4.17 AMENDMENT NO. 1 TO WARRANT TO PURCHASE EQUITY SECURITIES OF TETRALOGIC PHARMACEUTICALS CORPORATION THIS AMENDMENT NO. 1 (this “Amendment”), effective as of the day of October 2013, by and between TETRALOGIC PHARMACEUTICALS CORPORATION, a Delaware corporation (the “Company”), and [WARRANT HOLDER] (the “Holder”), amends certain warrants issued to Holder pursuant to that certain Note and |
|
| November 6, 2013 |
EX-3.2 3 a2217258zex-32.htm EX-3.2 Exhibit 3.2 TETRALOGIC PHARMACEUTICALS CORPORATION AMENDMENT NO. 2 TO FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify: FIRST: That the board of directors of the C |
|
| November 6, 2013 |
Exhibit 3.4 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TETRALOGIC PHARMACEUTICALS CORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) TetraLogic Pharmaceuticals Corporation (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DG |
|
| November 6, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION PERFORMANCE BONUS PLAN Exhibit 10.4 TETRALOGIC PHARMACEUTICALS CORPORATION PERFORMANCE BONUS PLAN Section 1. Purpose. The purpose of the TetraLogic Pharmaceuticals Corporation Performance Bonus Plan (the “Plan”) is to benefit and advance the interests of TetraLogic Pharmaceuticals Corporation, Inc., a Delaware corporation (the “Company”), by rewarding selected employees of the Company and its subsidiaries and divisions |
|
| November 6, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on November 6, 2013 Registration No. |
|
| November 6, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION 2013 EQUITY INCENTIVE PLAN Exhibit 10.3 TETRALOGIC PHARMACEUTICALS CORPORATION 2013 EQUITY INCENTIVE PLAN SECTION 1. Purpose; Definitions. The purposes of the TetraLogic Pharmaceutical Corporation 2013 Equity Incentive Plan (the “Plan”) are to: (a) enable TetraLogic Pharmaceutical Corporation (the “Company”) and its affiliated companies to recruit and retain highly qualified employees, directors and consultants; (b) provide |
|
| November 6, 2013 |
AMENDED AND RESTATED BYLAWS OF TETRALOGIC PHARMACEUTICALS CORPORATION Exhibit 3.6 AMENDED AND RESTATED BYLAWS OF TETRALOGIC PHARMACEUTICALS CORPORATION TABLE OF CONTENTS ARTICLE I STOCKHOLDERS 4 Section 1.1. Place of Meetings 4 Section 1.2. Annual Meeting 4 Section 1.3. Special Meetings 4 Section 1.4. Notification of Meetings 4 Section 1.5. Voting List 4 Section 1.6. Quorum 5 Section 1.7. Adjournments 5 Section 1.8. Voting and Proxies 5 Section 1.9. Action at Meetin |
|
| November 6, 2013 |
Exhibit 3.3 AMENDMENT NO. 3 TO THE FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF TETRALOGIC PHARMACEUTICALS CORPORATION Pursuant to Section 228 and Section 242 of the General Corporation Law of the State of Delaware (“DGCL”) TetraLogic Pharmaceuticals Corporation, a Delaware corporation (hereinafter called the “Corporation”), does hereby certify as follows: FIRST: That the board of d |
|
| November 6, 2013 |
Exhibit 10.18 THIRD AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT This Third Amended and Restated Investor Rights Agreement (the “Agreement”) is made as of , 2013, among TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), those stockholders of the Company listed on Exhibit A hereto (individually, a “Common Stockholder,” and collectively, the “Common Stockholders”), and |
|
| November 6, 2013 |
Exhibit 10.14 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made as of November , 2013 by and between TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous agreements between the Company and Indemnitee covering the subject matter of this Agreement, including without |
|
| November 6, 2013 |
The New York Times Building 37th Floor 620 Eighth Avenue New York, NY 10018-1405 212. |
|
| November 6, 2013 |
Exhibit 4.1 INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE COMMON STOCK FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE, OF TETRALOGIC PHARMACEUTICALS CORPORATION transferable on the books of the Corporation by the holder hereof in person or by Attorney upon surrender of this certificate properly endorsed. This cert |
|
| November 5, 2013 |
The New York Times Building 37th Floor 620 Eighth Avenue New York, NY 10018-1405 212. |
|
| October 31, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on October 31, 2013 Registration No. |
|
| October 31, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION UNSECURED CONVERTIBLE PROMISSORY NOTE Exhibit 4.16 THIS NOTE AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EXEMPTION FROM REGISTRATION OR AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT. TETRALOGIC PHARMACEUTICALS |
|
| October 31, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION WARRANT TO PURCHASE EQUITY SECURITIES EX-4.15 2 a2217143zex-415.htm EX-4.15 Exhibit 4.15 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGIST |
|
| October 24, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on October 24, 2013 Registration No. |
|
| October 23, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on October 23, 2013 Registration No. |
|
| October 18, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.11 TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of December 17, 2010 by and between David Weng (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”). Background WHEREAS, the Employee currently serv |
|
| October 18, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.9 TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 12, 2013 by and between Lesley Russell, M.D., a resident of Phoenixville, Pennsylvania (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”) |
|
| October 18, 2013 |
Exhibit 3.1 State of Delaware Secretary of State Division of Corporations Delivered 09:37 AM 05/20/2011 FILED 09:37 AM 05/20/2011 SRV 110582069 - 3705942 FILE TETRALOGIC PHARMACEUTICALS CORPORATION FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) TetraLogic Pharmaceuticals Corporation, a corporation |
|
| October 18, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION WARRANT TO PURCHASE EQUITY SECURITIES Exhibit 4.8 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. TETRALOGIC PHAR |
|
| October 18, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents As filed with the Securities and Exchange Commission on October 18, 2013 Registration No. |
|
| October 18, 2013 |
SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT Exhibit 4.14 SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT This Second Amended and Restated Right of First Refusal and Co-Sale Agreement (the “Agreement”) is made as of May 20, 2011 by and among certain holders of Common Stock listed on Exhibit A to this Agreement (“Common Holders”), TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and the |
|
| October 18, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.7 TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 12, 2013 by and between J. Kevin Buchi, a resident of Malvern, Pennsylvania (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”). Backgroun |
|
| October 18, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT EX-10.12 26 a2216962zex-1012.htm EX-10.12 Exhibit 10.12 TETRALOGIC PHARMACEUTICALS CORPORATION SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of December 17, 2010 by and between John M. Gill, a resident of Berwyn, Pennsylvania (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a cor |
|
| October 18, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION NOTE PURCHASE AGREEMENT Exhibit 4.12 TETRALOGIC PHARMACEUTICALS CORPORATION NOTE PURCHASE AGREEMENT TETRALOGIC PHARMACEUTICALS CORPORATION NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (the “Agreement”) is made as of the 16th day of May, 2013 (the “Effective Date”) by and among TETRALOGIC PHARMACEUTICALS CORPORATION, a Delaware corporation (the “Company”), and Amgen Inc. ( “Purchaser””). RECITAL To provide the Com |
|
| October 18, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION WARRANT TO PURCHASE EQUITY SECURITIES Exhibit 4.9 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. TETRALOGIC PHAR |
|
| October 18, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION 2004 EQUITY INCENTIVE PLAN Exhibit 10.2 TETRALOGIC PHARMACEUTICALS CORPORATION 2004 EQUITY INCENTIVE PLAN SECTION 1. Purpose; Definitions. The purposes of the Corporation 2004 Equity Incentive Plan (the “Plan”) are to: (a) enable TetraLogic Pharmaceuticals Corporation (the “Company”) and its affiliated companies to recruit and retain highly qualified employees, directors and consultants; (b) provide those employees, directo |
|
| October 18, 2013 |
EXCLUSIVE LICENSE AGREEMENT PRINCETON UNIVERSITY Exhibit 10.1 EXCLUSIVE LICENSE AGREEMENT between LICENSEE and PRINCETON UNIVERSITY Concerning Princeton Case Nos. Primary Inventor: George McLendon, Ph.D. AMENDED AND RESTATED LICENSE AGREEMENT THIS AMENDED AND RESTATED LICENSE AGREEMENT (the “Agreement”) is made and is effective as of the 6th day of October, 2006, by and between Princeton University, having its Office of Technology Licensing at 4 |
|
| October 18, 2013 |
EX-4.5 7 a2216962zex-45.htm EX-4.5 Exhibit 4.5 THIS WARRANT AND THE SHARES OF CAPITAL STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED TO ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION STATEMENT WITH RESPECT T |
|
| October 18, 2013 |
Exhibit 10.16 OFFICE/LABORATORY LEASE This LEASE, made this 30th day of April, 2004, by and between 335-95 Phoenixville Pike Associates a Pennsylvania Limited Partnership (hereinafter referred to as “Landlord”), and APOP Corporation. a Delaware Corporation (hereinafter referred to as “Tenant”); W I T N E S S E T H: 1. LEASED PREMISES. Landlord hereby demises and leases to Tenant that certain space |
|
| October 18, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.10 TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 14, 2012 (“Effective Date”) by and between C. Glenn Begley, M.B.B.S., Ph.D., F.R.A.C.P., F.R.C.P.A (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (t |
|
| October 18, 2013 |
The New York Times Building 37th Floor 620 Eighth Avenue New York, NY 10018-1405 212. |
|
| October 18, 2013 |
343 Phoenixville Pike · Malvern, PA 19355 · P 610.889.9900 · F 610.889.9994 www.tetralogicpharma.com Exhibit 10.13 November 13, 2012 Richard Sherman 4429 Kaluamakua Place Kilauea, HI 96754 Dear Dick: I am pleased to extend this offer for you to become the Senior Vice President Strategic Transactions and General Counsel of TetraLogic Pharmaceuticals subject to the following terms and conditions: Start Date You will become an employee of the Company on December 1, 2012 (your “Start Date”). Position |
|
| October 18, 2013 |
Exhibit 10.15 Advisory Services Agreement AGREEMENT made this 8 day of March, 2013, (“Effective Date”) between Andrew Pecora, M.D. (“Pecora”) and TetraLogic Pharmaceuticals Corporation (“TL”). WHEREAS, TL desires to obtain the services of Pecora to act as Chairman of the Board of Directors (“Board”) of TL; and WHEREAS, Pecora is willing to provide such services as an independent contractor and not |
|
| October 18, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION UNSECURED CONVERTIBLE PROMISSORY NOTE Exhibit 4.10 THIS NOTE AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EXEMPTION FROM REGISTRATION OR AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT. TETRALOGIC PHARMACEUTICALS |
|
| October 18, 2013 |
SECOND AMENDED AND RESTATED VOTING AGREEMENT Exhibit 4.13 SECOND AMENDED AND RESTATED VOTING AGREEMENT This Second Amended and Restated Voting Agreement (this “Voting Agreement”) is made as of May 20, 2011, among TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), certain holders of the Company’s Preferred Stock, severally and not jointly, listed on Exhibit A hereto (each of which is herein referred to as an “Inve |
|
| October 18, 2013 |
SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT Exhibit 10.17 SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT This Second Amended and Restated Investor Rights Agreement (the “Agreement”) is made as of May 20, 2011, among TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), those stockholders of the Company listed on Exhibit A hereto (individually, a “Common Stockholder,” and collectively, the “Common Stockholder |
|
| October 18, 2013 |
Exhibit 10.6 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is entered into as of this 12th day of August, 2013 (the “Effective Date”) by and between TetraLogic Pharmaceuticals Corporation (“TetraLogic”), a Delaware corporation with its principal place of business located at 343 Phoenixville Pike, Malvern, Pa. 19355 and John M. Gill, having an address at 822 Nathan Hole Road, Be |
|
| October 18, 2013 |
Exhibit 4.7 THIS WARRANT AND THE SHARES OF CAPITAL STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OK 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED TO ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION STATEMENT WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE |
|
| October 18, 2013 |
Exhibit 4.3 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, I |
|
| October 18, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION UNSECURED CONVERTIBLE PROMISSORY NOTE Exhibit 4.11 THIS NOTE AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EXEMPTION FROM REGISTRATION OR AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT. TETRALOGIC PHARMACEUTICALS |
|
| October 18, 2013 |
MANAGEMENT TRANSITION AGREEMENT Exhibit 10.5 MANAGEMENT TRANSITION AGREEMENT This Agreement is being entered into as of the 12th day of August, 2013 by and between TetraLogic Pharmaceuticals Corporation (hereinafter “Company”), and Mr. John M. Gill (hereinafter “Gill”). WHEREAS, Gill is employed by Company as President and Chief Executive Officer; WHEREAS, Gill and Company have mutually agreed that Gill resign his employment wit |
|
| October 18, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.8 TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 12, 2013 by and between Pete A. Meyers, a resident of Malvern, Pennsylvania (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”). Backgroun |
|
| October 18, 2013 |
BYLAWS OF GENTARA CORPORATION (a Delaware Corporation) ARTICLE 1 OFFICES AND FISCAL YEAR Exhibit 3.4 BYLAWS OF GENTARA CORPORATION (a Delaware Corporation) ARTICLE 1 OFFICES AND FISCAL YEAR SECTION 1.01. Registered Office. The registered office of the corporation shall be in the City of Wilmington, County of New Castle, State of Delaware until otherwise established by resolution of the board of directors, and a certificate certifying the change is filed in the manner provided by statu |
|
| October 18, 2013 |
Exhibit 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT AND LAWS OR, SUBJECT TO SECTION 5.3 HEREOF, AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL, TH |
|
| October 18, 2013 |
Exhibit 4.4 THIS WARRANT AND THE SHARES OF CAPITAL STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED TO ANY PERSON, INCLUDING A PLEDGEE, UNLESS (I) EITHER (A) A REGISTRATION STATEMENT WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE |
|
| October 18, 2013 |
Exhibit 4.6 THIS WARRANT AND THE SHARES OF CAPITAL STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OK 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED TO ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISRATION STATEMENT WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE |
|
| September 16, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.8 TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 12, 2013 by and between Pete A. Meyers, a resident of Malvern, Pennsylvania (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”). Backgroun |
|
| September 16, 2013 |
SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT Exhibit 10.16 SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT This Second Amended and Restated Investor Rights Agreement (the “Agreement”) is made as of May 20, 2011, among TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), those stockholders of the Company listed on Exhibit A hereto (individually, a “Common Stockholder,” and collectively, the “Common Stockholder |
|
| September 16, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.11 TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of December 17, 2010 by and between David Weng (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”). Background WHEREAS, the Employee currently serv |
|
| September 16, 2013 |
Exhibit 4.7 THIS WARRANT AND THE SHARES OF CAPITAL STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OK 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED TO ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION STATEMENT WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE |
|
| September 16, 2013 |
Exhibit 4.5 THIS WARRANT AND THE SHARES OF CAPITAL STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED TO ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISTRATION STATEMENT WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE |
|
| September 16, 2013 |
Exhibit 4.3 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR, I |
|
| September 16, 2013 |
Exhibit 4.2 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT AND LAWS OR, SUBJECT TO SECTION 5.3 HEREOF, AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL, TH |
|
| September 16, 2013 |
Exhibit 10.14 Advisory Services Agreement AGREEMENT made this 8 day of March, 2013, (“Effective Date”) between Andrew Pecora, M.D. (“Pecora”) and TetraLogic Pharmaceuticals Corporation (“TL”). WHEREAS, TL desires to obtain the services of Pecora to act as Chairman of the Board of Directors (“Board”) of TL; and WHEREAS, Pecora is willing to provide such services as an independent contractor and not |
|
| September 16, 2013 |
September 16, 2013 CONFIDENTIAL SUBMISSION U.S. Securities and Exchange Commission Draft Registration Statement U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Confidential Submission Pursuant to Title 1, Section 106 under the Jumpstart Our Business Startups Act And Section 24(b)(2) of the Securities Exchange Act of 1934 Re: Confidential Submission of Draft Registra |
|
| September 16, 2013 |
Exhibit 10.15 OFFICE/LABORATORY LEASE This LEASE, made this 30th day of April, 2004, by and between 335-95 Phoenixville Pike Associates a Pennsylvania Limited Partnership (hereinafter referred to as “Landlord”), and APOP Corporation. a Delaware Corporation (hereinafter referred to as “Tenant”); W I T N E S S E T H: 1. LEASED PREMISES. Landlord hereby demises and leases to Tenant that certain space |
|
| September 16, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.7 TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 12, 2013 by and between J. Kevin Buchi, a resident of Malvern, Pennsylvania (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”). Backgroun |
|
| September 16, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION UNSECURED CONVERTIBLE PROMISSORY NOTE Exhibit 4.10 THIS NOTE AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EXEMPTION FROM REGISTRATION OR AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT. TETRALOGIC PHARMACEUTICALS |
|
| September 16, 2013 |
Exhibit 10.2 TETRALOGIC PHARMACEUTICALS CORPORATION 2004 EQUITY INCENTIVE PLAN SECTION 1. Purpose; Definitions. The purposes of the Corporation 2004 Equity Incentive Plan (the “Plan”) are to: (a) enable TetraLogic Pharmaceuticals Corporation (the “Company”) and its affiliated companies to recruit and retain highly qualified employees, directors and consultants; (b) provide those employees, directo |
|
| September 16, 2013 |
343 Phoenixville Pike · Malvern, PA 19355 · P 610.889.9900 · F 610.889.9994 www.tetralogicpharma.com Exhibit 10.12 November 13, 2012 Richard Sherman 4429 Kaluamakua Place Kilauea, HI 96754 Dear Dick: I am pleased to extend this offer for you to become the Senior Vice President Strategic Transactions and General Counsel of TetraLogic Pharmaceuticals subject to the following terms and conditions: Start Date You will become an employee of the Company on December 1, 2012 (your “Start Date”). Position |
|
| September 16, 2013 |
EXCLUSIVE LICENSE AGREEMENT PRINCETON UNIVERSITY Exhibit 10.1 EXCLUSIVE LICENSE AGREEMENT between LICENSEE and PRINCETON UNIVERSITY Concerning Princeton Case Nos. Primary Inventor: George McLendon, Ph.D. AMENDED AND RESTATED LICENSE AGREEMENT THIS AMENDED AND RESTATED LICENSE AGREEMENT (the “Agreement”) is made and is effective as of the 6th day of October, 2006, by and between Princeton University, having its Office of Technology Licensing at 4 |
|
| September 16, 2013 |
Exhibit 4.4 THIS WARRANT AND THE SHARES OF CAPITAL STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED TO ANY PERSON, INCLUDING A PLEDGEE, UNLESS (I) EITHER (A) A REGISTRATION STATEMENT WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE |
|
| September 16, 2013 |
SECOND AMENDED AND RESTATED VOTING AGREEMENT Exhibit 4.13 SECOND AMENDED AND RESTATED VOTING AGREEMENT This Second Amended and Restated Voting Agreement (this “Voting Agreement”) is made as of May 20, 2011, among TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), certain holders of the Company’s Preferred Stock, severally and not jointly, listed on Exhibit A hereto (each of which is herein referred to as an “Inve |
|
| September 16, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.10 TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 14, 2012 (“Effective Date”) by and between C. Glenn Begley, M.B.B.S., Ph.D., F.R.A.C.P., F.R.C.P.A (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State of Delaware (t |
|
| September 16, 2013 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 16, 2013 Registration No. |
|
| September 16, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION NOTE PURCHASE AGREEMENT Exhibit 4.12 TETRALOGIC PHARMACEUTICALS CORPORATION NOTE PURCHASE AGREEMENT TETRALOGIC PHARMACEUTICALS CORPORATION NOTE PURCHASE AGREEMENT THIS NOTE PURCHASE AGREEMENT (the “Agreement”) is made as of the 16th day of May, 2013 (the “Effective Date”) by and among TETRALOGIC PHARMACEUTICALS CORPORATION, a Delaware corporation (the “Company”), and Amgen Inc. ( “Purchaser””). RECITAL To provide the Com |
|
| September 16, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT EX-10.9 20 filename20.htm Exhibit 10.9 TETRALOGIC PHARMACEUTICALS CORPORATION EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made as of August 12, 2013 by and between Lesley Russell, M.D., a resident of Phoenixville, Pennsylvania (the “Employee”), and TetraLogic Pharmaceuticals Corporation, a corporation organized and existing under the laws of the State o |
|
| September 16, 2013 |
EX-10.6 17 filename17.htm Exhibit 10.6 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is entered into as of this 12th day of August, 2013 (the “Effective Date”) by and between TetraLogic Pharmaceuticals Corporation (“TetraLogic”), a Delaware corporation with its principal place of business located at 343 Phoenixville Pike, Malvern, Pa. 19355 and John M. Gill, having an address a |
|
| September 16, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION UNSECURED CONVERTIBLE PROMISSORY NOTE Exhibit 4.11 THIS NOTE AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EXEMPTION FROM REGISTRATION OR AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT. TETRALOGIC PHARMACEUTICALS |
|
| September 16, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION WARRANT TO PURCHASE EQUITY SECURITIES Exhibit 4.9 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. TETRALOGIC PHAR |
|
| September 16, 2013 |
Exhibit 4.6 THIS WARRANT AND THE SHARES OF CAPITAL STOCK ISSUED UPON ANY EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OK 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED TO ANY PERSON, INCLUDING A PLEDGEE, UNLESS (1) EITHER (A) A REGISRATION STATEMENT WITH RESPECT THERETO SHALL BE EFFECTIVE UNDER THE |
|
| September 16, 2013 |
TETRALOGIC PHARMACEUTICALS CORPORATION WARRANT TO PURCHASE EQUITY SECURITIES Exhibit 4.8 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. TETRALOGIC PHAR |
|
| September 16, 2013 |
SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT Exhibit 4.14 SECOND AMENDED AND RESTATED RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT This Second Amended and Restated Right of First Refusal and Co-Sale Agreement (the “Agreement”) is made as of May 20, 2011 by and among certain holders of Common Stock listed on Exhibit A to this Agreement (“Common Holders”), TetraLogic Pharmaceuticals Corporation, a Delaware corporation (the “Company”), and the |
